Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Non-Current Liabilities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $49.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 1.56% to $49.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.2 million through Dec 2025, up 1.56% year-over-year, with the annual reading at $46.0 million for FY2025, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $49.2 million at Outlook Therapeutics, up from $46.0 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $52.1 million in Q2 2025, with the low at $46.0 million in Q3 2025.